The standard of care for resected, high‐risk melanoma now consists of an array of novel therapeutics, including immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab, or dabrafenib/trametinib among individuals with a BRAF V600 activating mutation,3 all of which are significantly more expensive than the previous generation of treatments.5, 26. The gene discussed is BRAF; the disease is melanoma.